三博脑科：公司神经调控技术带来的收入占公司营业收入比重很小，对公司业绩基本没有影响

Core Viewpoint - Sanbo Brain Science (301293.SZ) is making progress in its brain-computer interface (BCI) business, but its main revenue still comes from high-end neurosurgery services, with BCI technology currently contributing minimally to overall performance [2]. Group 1: Surgical Trials - The company has completed one interventional brain-computer interface surgery at its Fujian branch, with no other surgeries reported within the group [2]. Group 2: External Investment and Collaboration - Sanbo Brain Science has previously invested in three brain science funds and has established a joint research center for precision medicine in collaboration with Tsinghua University’s School of Biomedical Engineering [2]. - Ongoing projects related to these collaborations are still in progress [2]. Group 3: Revenue Impact - The revenue generated from the company's neuromodulation technology is currently very small, having a negligible impact on the company's overall performance [2].